These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088 [TBL] [Abstract][Full Text] [Related]
8. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Olson KE; Gendelman HE Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205 [TBL] [Abstract][Full Text] [Related]
9. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. Gelders G; Baekelandt V; Van der Perren A J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629 [TBL] [Abstract][Full Text] [Related]
10. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550 [TBL] [Abstract][Full Text] [Related]
11. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825 [TBL] [Abstract][Full Text] [Related]
12. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays. Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145 [TBL] [Abstract][Full Text] [Related]
13. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222 [TBL] [Abstract][Full Text] [Related]
15. Enzyme-linked immunosorbent assays for α-synuclein with species and multimeric state specificities. Lee HJ; Bae EJ; Jang A; Ho DH; Cho ED; Suk JE; Yun YM; Lee SJ J Neurosci Methods; 2011 Aug; 199(2):249-57. PubMed ID: 21658411 [TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease. Kim S; Seo JH; Suh YH Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581 [TBL] [Abstract][Full Text] [Related]
18. Development of Passive Immunotherapies for Synucleinopathies. Bergström AL; Kallunki P; Fog K Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735 [TBL] [Abstract][Full Text] [Related]
20. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Romero-Ramos M; von Euler Chelpin M; Sanchez-Guajardo V Hum Vaccin Immunother; 2014; 10(4):852-67. PubMed ID: 24670306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]